EyePoint’s Duravyu falls short to Eylea in Phase III trial
EyePoint’s stock dropped 67% after its potential Eylea (aflibercept) competitor Duravyu fell short in a Phase III trial…
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog.…